Can You Take Semaglutide More Than Once a Week?

Why does semaglutide only work as a once-weekly dose?

Semaglutide's half-life (the time it takes for half the drug to leave your body) is roughly seven days. That is not a coincidence; Novo Nordisk engineered the molecule specifically so one injection sustains consistent blood levels across an entire week. By the time day seven arrives, levels have dipped just enough to be ready for the next pen. The steady-state this creates is what produces the appetite-suppressing and metabolic effects seen in the STEP trials.

Taking a second injection mid-week would not boost that effect; drug levels would climb into a range the body has not adapted to, and the GI consequences tend to follow quickly. Nausea, vomiting, and in more severe cases dehydration serious enough to affect the kidneys are the predictable results of stacking doses. A question our prescribers hear most weeks is whether taking it slightly early (say, on day five or six) counts as the same problem. It depends on the gap, and it is always worth checking with the clinical team rather than guessing.

The once-weekly Wegovy schedule is governed by the medicine's licence; altering it puts you outside that authorised use, which matters both for safety and for the clinical oversight your prescriber provides.

What actually happens if you take Wegovy more than once a week?

The honest answer is: nothing beneficial, and potentially something harmful. Semaglutide's GLP-1 action is already at full stretch during your normal dosing window. A second injection within the same seven-day period adds drug load without adding receptor capacity, the receptors are already engaged. What you get instead is amplified side effects: intensified nausea, more pronounced slowing of gastric emptying, and a higher chance of vomiting that tips into clinical dehydration.

There is also the prescriber relationship to consider. Wegovy is a prescription-only medicine, and if you are still getting to grips with the basics, it helps to know how to pronounce Wegovy correctly before speaking with your clinical team, since clear communication matters at every stage of treatment. If a prescriber does not know you have doubled up, they cannot make safe decisions about your next dose increase. Transparency with your clinical team matters more than it might seem.

If you are wondering whether you can space doses further apart rather than closer together, that comes with its own set of considerations worth reading separately.

Does the titration schedule mean slower results?

The titration ladder (starting at 0.25mg and climbing through 0.5mg, 1.0mg, 1.7mg and eventually 2.4mg (or 7.2mg under the updated licence)) is one of the things people push back against most. It feels slow when you are keen to see progress. But the pacing is about tolerability, not caution for its own sake. Moving too fast through the doses is the most common reason people abandon treatment altogether because the side effects become unmanageable.

Results do build as the dose increases, and the STEP 1 trial (published in the New England Journal of Medicine) reported an average body-weight reduction of around 15% at the 2.4mg maintenance dose over 68 weeks. That outcome came from participants following the prescribed schedule. There is no evidence that compressing the timeline produces better results; the data suggests the opposite.

For a broader picture of how semaglutide works as a treatment, including how the dose-escalation process is managed clinically, that page covers the mechanism in more detail. And if you are already on treatment and thinking about what happens during a dose increase, the considerations around adjusting your semaglutide dose are worth reviewing with your prescriber before making any changes.

What should you do if you think your dose is not working?

The feeling that the current dose is doing nothing (especially in the earlier stages) is genuinely common. Appetite suppression at 0.25mg is often subtle. Some people barely notice it. That does not mean the medicine is failing; it means the dose has not yet reached the therapeutic range. The answer is not a second injection; it is a prescriber conversation about whether a dose increase is appropriate and on schedule.

If you have already reached the maintenance dose and weight loss has stalled, there are clinical reasons for that too (plateau effects, changes in activity levels, or individual pharmacokinetics) and again, the route forward is through your prescriber rather than around them. You can also read about what happens when you take a break from Wegovy, since that is a related question that often comes up alongside concerns about effectiveness. For anyone considering starting treatment or switching from another service, checking your eligibility through a clinical consultation is the right first step.